Abstract library

195 results for "oesophageal nec".
#1500 Analysis of Oesophageal Neuroendocrine Tumour Outcomes
Introduction: Oesophageal Neuroendocrine Tumours(NETs) are rare neoplasms accounting for <2% of Gastroenteropancreatic NET(GEP NETs).
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Apostolos Koffas
Keywords: oesophageal nec
#1678 Multicenter Retrospective Analysis of Clinical and Pathological Features of Gastroesophageal Junction Neuroendocrine Neoplasm(GEJ-NEN)
Introduction: GEJ-NEN is mostly poorly differentiated NEC with poor prognosis.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Panpan Zhang
Authors: Zhang P, Lu M, Shen L, Wang W, ...
#2793 A Phase II, Open-Label, Multicenter Trial of Avelumab in Patients with Advanced, Metastatic High Grade Neuroendocrine Carcinomas NEC G3 (WHO 2010) Progressive after First-line Chemotherapy (AVENEC)
Introduction: High grade Neuroendocrine Neoplasias (NEN) are rare tumors with a poor prognosis and no established second line therapy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: PD. Dr. Christian Fottner
#443 Neuroendocrine Carcinoma (NEC) and Composite Exocrine-Neuroendocrine Carcinoma (CENEC) of the Stomach: A Clinicopathological Review of 58 Cases
Introduction: NEC of the stomach is an uncommon tumor accounting for 0.5% of all gastric carcinomas and about 6% of gastric NETs. CENEC contain both areas of NEC and conventional carcinoma. The histological diagnosis is difficult.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Vladimir Khomyakov
#1551 Establishment and Characterization of Three GEP-NEC Cell Lines for In Vitro and In Vivo Studies
Introduction: To date chemotherapeutic concepts applying cisplatin/etoposide for the treatment of highly aggressive GEP-NEC do not provide convincing results. Thus, there is an urgent need for NEC cell line models that provide a reliable experimental system in identifying novel therapeutic targets.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr. Andreas Krieg
Authors: Krieg A, Riemer J C, Dizdar L, Mersch S, ...
Keywords: GEP-NEC
#2279 Expression of FOXM1 in G3 Neuroendocrine Tumors (NET G3) and G3 Neuroendocrine Carcinomas (NEC G3) of the Pancreas and the Intestine
Introduction: G3 gastroenteropancreatic neuroendocrine tumors (G3 NET) and carcinomas (G3 NEC) differ considerably concerning their biological behavior and patients outcome. Whereas the WHO2017 classification for pancreatic NETs proposes a distinction of both groups using the Ki-67 proliferation marker (Klöppel et al. Reviews and Reports 2017), a useful marker for the subclassification of G3 intestinal NETs have not been recommended until now.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Franziska Briest
#1211 Lack of Efficacy of Anthracycline-Containing Second Line Chemotherapy in Patients with GI-NEC After Cisplatin-Based Treatment
Introduction: Little is known about optimal 2nd-line treatment in patients with GI-NEC failing cisplatin-based therapy.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Barbara Kiesewetter
Keywords: GI-NEC
#608 Is Octreotide Benefitial in Patients with Metastatic Gastroenteropancreatic (GEP) and Hepatobiliary Neuroendocrine Carcinoma (NEC)?
Introduction: Neuroendocrine carcinomas (NECs) of the gastroenteropancreatic (GEP) and hepatobiliary (HB) tract are rare and a heterogenous group of malignancies. Octreotide showed the anti-tumor activity in well-differentiated metastatic midgut neuroendocrine tumors (NETs).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Seung Kim
Authors: Kim S, ...
Keywords: NEC, octreotide, GEP, HB
#1204 Clinico-Pathologic and Survival Analysis of 211 GastroEnteroPancreatic G3 Neuroendocrine Carcinomas (GEP-NECs)
Introduction: GEP-NECs show Ki67>20% and/or >20 mitoses x10 HPF. Mixed AdenoNeuroendocrine Carcinomas (MANECs) are mixed exocrine-neuroendocrine neoplasms. NECs are associated with poor prognosis but recent findings have suggested that there is a fraction of patients showing a better than expected survival rate.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Pathology, grading, staging
Presenting Author: MD, PhD Massimo Milione
Keywords: NEC, Ki67, MANEC, PROGNOSIS
#2875 Immunotherapy as Second-line Treatment in Grade 3 Neuroendocrine Carcinomas: A Prospective Case Series from an ENETS Center of Excellence
Introduction: Metastatic WHO grade 3 extra-pulmonary neuroendocrine carcinomas (EP-NEC) have a poor prognosis and optimal treatment after first-line platinum-etoposide chemotherapy remains unclear. A recent, small phase II study combining ipilimumab and nivolumab showed promising results
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Timon Vandamme
Keywords: NEC, immunotherapy